Multisite Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex TEMPORARY CLOSURE

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations dated 11/26/2019

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations

Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.

Molecular Analysis for Therapy Choice (MATCH)

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol A: EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C2: EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol M: EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1C: EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1K: EAY131-Z1K: Ipatasertib in Patients with Tumors with AKT Mutations

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)

Work Ability in Young Adult Survivors (WAYS)

Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
   Patients must be < 50 Years of Age at Enrollment.
2. Standard Risk 1
   Patient must be < 11 Years of Age at Enrollment.
3. Standard Risk 2
   Patients must be ≥ 11 and < 25 Years of Age at Enrollment.

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification